Amgen Inc. (4332.HK)
| Previous close | 1,850.000 |
| Open | 1,761.000 |
| Bid | 1,761.000 x N/A |
| Ask | 0.000 x N/A |
| Day's range | 1,761.000 - 1,761.000 |
| 52-week range | 1,761.000 - 1,850.000 |
| Volume | |
| Avg. volume | 0 |
| Market cap | 1.089T |
| Beta (5Y monthly) | 0.58 |
| PE ratio (TTM) | 16.03 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 66.66 (3.60%) |
| Ex-dividend date | 16 Nov 2023 |
| 1y target est | N/A |
- PR Newswire
FDA APPROVES IMDELLTRA™ (TARLATAMAB-DLLE), THE FIRST AND ONLY T-CELL ENGAGER THERAPY FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER
Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved IMDELLTRA™ (tarlatamab-dlle) for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy. IMDELLTRA has received accelerated approval based on the encouraging response rate and duration of response (DoR) observed in clinical studies. Continued approval for this indication may be contingent upon verificatio
- PR Newswire
AMGEN TO HOST CONFERENCE CALL FOLLOWING ATS 2024
Amgen (NASDAQ:AMGN) will host a webcasted call for the investment community at 1:00 p.m. PT on Monday, May 20, 2024 following the presentation of new data from TEZSPIRE® in chronic obstructive pulmonary disease (COPD) at the American Thoracic Society (ATS) International Conference on May 19 and 20, 2024. The presentation will also include an overview of additional programs from Amgen's innovative inflammation portfolio. Jay Bradner, executive vice president of Research and Development and chief
- PR Newswire
AMGEN TO PRESENT AT THE BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE
Amgen (NASDAQ:AMGN) will present at the Bank of America Merrill Lynch Global Healthcare Conference at 9:20 a.m. PT on Tuesday, May 14, 2024. Peter Griffith, executive vice president and chief financial officer at Amgen, and Jay Bradner, executive vice president of Research and Development and chief scientific officer at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the genera
